Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

NCT01960023 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT01960023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01960023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab
Lead sponsor
NSABP Foundation Inc
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 31, 2013
Completion date
July 13, 2016
Enrollment
0 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer